Skip to main content
. Author manuscript; available in PMC: 2021 May 17.
Published in final edited form as: Clin Cancer Res. 2018 Dec 4;25(6):1809–1816. doi: 10.1158/1078-0432.CCR-18-3181

Table 1.

Patient origin (trial) and baseline characteristics of split datasets

Training cohort (%)
Test cohort (%)
all-P (n = 2,021) rand-P (n = 863) all-P (n = 2,020) rand-P (n = 862)
Trial
  CENTRIC (randomized) 264 (13.1) 264 (30.6) 262 (13.0) 262 (30.4)
  CENTRIC (screened) 1,058 (52.4) NA 1,058 (52.4) NA
  CORE (randomized) 132 (6.5) 132 (15.3) 133 (6.6) 133 (15.4)
  CORE (screened) 100 (4.9) NA 100 (5.0) NA
  AVAGlio 170 (8.4) 170 (19.7) 170 (8.4) 170 (19.7)
  RTOG 0825 297 (14.7) 297 (34.4) 297 (14.7) 297 (34.5)
Baseline characteristics
 Performance status (randomized patients only)
  PS = 0 NA 516 (59.8) NA 514 (59.6)
  PS ≥ 1 NA 347 (40.2) NA 345 (40.0)
  Missing NA 0(0) NA 3 (0.4)
 Extent of resection (randomized patients only)
  Complete resection NA 454 (52.6) NA 453 (52.6)
  Partial resection NA 394 (45.7) NA 392 (45.5)
  Biopsy only NA 6 (0.7) NA 7 (0.8)
  Other NA 8 (0.9) NA 8 (0.9)
  Missing NA 1 (0.1) NA 2 (0.2)
 Age in years (randomized patients only)
  Median (Q1, Q3) NA 57 (50, 63) NA 57.5 (50, 64)
 Corrected log2 MGMT ratio
  Median (Q1, Q3) −0.58 (−2.00, 3.24) 0.63 (−1.97, 4.77) −0.58 (−1.96, 3.54). 1.06 (−1.79, 4.94)